(firstQuint)Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer.

 This is a phase II,single center,prospective, single arm clinical trials.

 The objective is to evaluate the efficacy and safetyof Epalrestat in the treatment of metastatic triple negative breast.

Primary endpoint is 16-week clinical benefit rate (CBR).

.

 Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer@highlight

To evaluate the efficacy and safety of Epalrestat in the treatment of metastatic triple negative breast